Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Squire

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
BMJ Open|May 28, 2025
Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial - REACH-HFpEF trialRod S Taylor, Emma Burrell, Claire O'Hare, et al.
BMC Cardiovascular Disorders|July 5, 2024
Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record dataFardad Soltani, David A Jenkins, Amit Kaura, et al.
European Journal of Heart Failure|March 2, 2026
SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart FailureRoss T Campbell, Joanna Osmanska, Kieran F Docherty, et al.
Frontiers in Cardiovascular Medicine|June 5, 2024
Changes in the investigation and management of suspected myocardial infarction and injury during COVID-19: a multi-centre study using routinely collected healthcare dataLara Chammas, Kevin Yuan, Stephanie Little, et al.
The Lancet. Public Health|November 1, 2024
Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health recordsRobert A Fletcher, Patrick Rockenschaub, Brendon L Neuen, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Heart Journal|November 23, 2014
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureJohn McMurray, Milton Packer, Akshay Desai, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
BMJ Open|May 28, 2025
Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial - REACH-HFpEF trialRod S Taylor, Emma Burrell, Claire O'Hare, et al.
BMC Cardiovascular Disorders|July 5, 2024
Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record dataFardad Soltani, David A Jenkins, Amit Kaura, et al.
European Journal of Heart Failure|March 2, 2026
SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart FailureRoss T Campbell, Joanna Osmanska, Kieran F Docherty, et al.
Frontiers in Cardiovascular Medicine|June 5, 2024
Changes in the investigation and management of suspected myocardial infarction and injury during COVID-19: a multi-centre study using routinely collected healthcare dataLara Chammas, Kevin Yuan, Stephanie Little, et al.
The Lancet. Public Health|November 1, 2024
Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health recordsRobert A Fletcher, Patrick Rockenschaub, Brendon L Neuen, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Heart Journal|November 23, 2014
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureJohn McMurray, Milton Packer, Akshay Desai, et al.
Pageof 8